Literature DB >> 27830455

Optimization of an endovascular magnetic filter for maximized capture of magnetic nanoparticles.

Sravani Kondapavulur1,2, Andre M Cote1, Kiel D Neumann1, Caroline D Jordan1, David McCoy1, Marc C Mabray1, Derek Liu2, Chia-Hung Sze1, Ayushi Gautam1, Henry F VanBrocklin1, Mark Wilson1, Steven W Hetts3.   

Abstract

To computationally optimize the design of an endovascular magnetic filtration device that binds iron oxide nanoparticles and to validate simulations with experimental results of prototype devices in physiologic flow testing. Three-dimensional computational models of different endovascular magnetic filter devices assessed magnetic particle capture. We simulated a series of cylindrical neodymium N52 magnets and capture of 1500 iron oxide nanoparticles infused in a simulated 14 mm-diameter vessel. Device parameters varied included: magnetization orientation (across the diameter, "D", along the length, "L", of the filter), magnet outer diameter (3, 4, 5 mm), magnet length (5, 10 mm), and spacing between magnets (1, 3 mm). Top designs were tested in vitro using 89Zr-radiolabeled iron oxide nanoparticles and gamma counting both in continuous and multiple pass flow model. Computationally, "D" magnetized devices had greater capture than "L" magnetized devices. Increasing outer diameter of magnets increased particle capture as follows: "D" designs, 3 mm: 12.8-13.6 %, 4 mm: 16.6-17.6 %, 5 mm: 21.8-24.6 %; "L" designs, 3 mm: 5.6-10 %, 4 mm: 9.4-15.8 %, 5 mm: 14.8-21.2 %. In vitro, while there was significant capture by all device designs, with most capturing 87-93 % within the first two minutes, compared to control non-magnetic devices, there was no significant difference in particle capture with the parameters varied. The computational study predicts that endovascular magnetic filters demonstrate maximum particle capture with "D" magnetization. In vitro flow testing demonstrated no difference in capture with varied parameters. Clinically, "D" magnetized devices would be most practical, sized as large as possible without causing intravascular flow obstruction.

Entities:  

Keywords:  Chemofiltration; Endovascular device; Intra-arterial chemotherapy (IAC); Magnetic nanoparticles

Mesh:

Substances:

Year:  2016        PMID: 27830455      PMCID: PMC5468174          DOI: 10.1007/s10544-016-0135-2

Source DB:  PubMed          Journal:  Biomed Microdevices        ISSN: 1387-2176            Impact factor:   2.838


  18 in total

1.  Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.

Authors:  Myeong Jun Song; Ho Jong Chun; Do Seon Song; Hee Yeon Kim; Sun Hong Yoo; Chung-Hwa Park; Si Hyun Bae; Jong Young Choi; U Im Chang; Jin Mo Yang; Hae Giu Lee; Seung Kew Yoon
Journal:  J Hepatol       Date:  2012-07-20       Impact factor: 25.083

2.  A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting.

Authors:  J Gautier; E Munnier; A Paillard; K Hervé; L Douziech-Eyrolles; M Soucé; P Dubois; I Chourpa
Journal:  Int J Pharm       Date:  2011-06-15       Impact factor: 5.875

3.  Single-dose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier.

Authors:  S C Goodwin; C A Bittner; C L Peterson; G Wong
Journal:  Toxicol Sci       Date:  2001-03       Impact factor: 4.849

4.  Analytical model of magnetic nanoparticle transport and capture in the microvasculature.

Authors:  E P Furlani; K C Ng
Journal:  Phys Rev E Stat Nonlin Soft Matter Phys       Date:  2006-06-27

5.  Development and Validation of Endovascular Chemotherapy Filter Device for Removing High-Dose Doxorubicin: Preclinical Study.

Authors:  Anand S Patel; Maythem Saeed; Erin J Yee; Jeffrey Yang; Gregory J Lam; Aaron D Losey; Prasheel V Lillaney; Bradford Thorne; Albert K Chin; Sheena Malik; Mark W Wilson; Xi C Chen; Nitash P Balsara; Steven W Hetts
Journal:  J Med Device       Date:  2014-08-19       Impact factor: 0.582

6.  Reduction of systemic drug exposure after hepatic arterial infusion of doxorubicin with complete hepatic venous isolation and extracorporeal chemofiltration.

Authors:  S A Curley; D R Byrd; R A Newman; H J Ellis; J Chase; C H Carrasco; K Cleary; W Bodden; D C Hohn
Journal:  Surgery       Date:  1993-09       Impact factor: 3.982

7.  Computational simulations of magnetic particle capture in arterial flows.

Authors:  J W Haverkort; S Kenjeres; C R Kleijn
Journal:  Ann Biomed Eng       Date:  2009-09-16       Impact factor: 3.934

8.  Magnetic targeting of microspheres in blood flow.

Authors:  C F Driscoll; R M Morris; A E Senyei; K J Widder; G S Heller
Journal:  Microvasc Res       Date:  1984-05       Impact factor: 3.514

9.  Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: a phase I study.

Authors:  S A Curley; R A Newman; T B Dougherty; G M Fuhrman; D L Stone; J A Mikolajek; S Guercio; A Guercio; C H Carrasco; M T Kuo
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

10.  Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Authors:  Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-12       Impact factor: 2.740

View more
  1 in total

1.  Quantification of 89 Zr-Iron oxide nanoparticle biodistribution using PET-MR and ultrashort TE sequences.

Authors:  Caroline D Jordan; Misung Han; Sravani Kondapavulur; Denis Beckford Vera; Kiel D Neumann; Teri Moore; Carol Stillson; Roland Krug; Spencer Behr; Youngho Seo; Henry F VanBrocklin; Peder E Z Larson; Mark Wilson; Alastair J Martin; Steven W Hetts
Journal:  J Magn Reson Imaging       Date:  2018-05-14       Impact factor: 4.813

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.